Custom service
Designing Peptides for Antibody Production
Design immunogenic peptide antigens and choose carriers and adjuvant strategy
The service is built around antigenicity and surface-exposure prediction. Depending on the molecule we may move to carrier conjugation planning or species-specific T-cell epitope checks to improve stability, loading or yield, and every batch is released with immunogen design package.
Because Designing Peptides for Antibody Production projects usually feed a downstream assay or preclinical study, we lock the release specification early — purity, identity and functional readouts are agreed at quotation, not discovered at delivery.
Polyclonal and monoclonal antibody immunogens
Avoiding epitopes conserved with the host proteome
Guarantees on the resulting antibody titre
Sequences where a recombinant expression route is objectively cheaper and faster
Release specification is fixed at quotation: standard >95% by HPLC, >98% for assay-critical material. Long chains (>60 residues) are additionally confirmed by MS/MS sequence coverage, and truncated-deletion species are quantified, not just summarized.
Service Highlights
- Antigenicity and surface-exposure prediction as the default route, with carrier conjugation planning held as a proven fallback
- Species-specific T-cell epitope checks worked into the design where the application requires it
- Sequence difficulty analysis (aggregation risk, motif hazards) is done before synthesis, and the route is chosen around it
- Analytical confirmation of every intermediate before the final release
- Microwave-assisted coupling and double-coupling are applied automatically where the sequence demands them
- Immunogen design package delivered with a complete conjugation or synthesis certificate
How the work runs
Sequence analysis
Designing Peptides for Antibody Production is analyzed for aggregation risk, motif hazards and puri?cation difficulty before a route is quoted.
Route selection
Fmoc solid-phase, fragment ligation or hybrid solution-phase is selected and documented.
Assembly
The chain is built with antigenicity and surface-exposure prediction applied where the sequence demands it, with double-coupling at hazard sites.
Cleavage & crude QC
Crude material is characterized so purification targets are set on data, not hope.
Purification
RP-HPLC (and ion-exchange where needed) delivers the agreed purity; fractions are pooled on MS confirmation.
Release
Immunogen design package is documented with the full analytical package and released.
Specifications & timeline
- Turnaround
- 2–3 weeks
- Typical scale
- 0.1 mg – 10 g per sequence
- Chemistry options
- antigenicity and surface-exposure prediction; carrier conjugation planning; species-specific T-cell epitope checks
- Deliverable
- Immunogen design package
- QC package
- HPLC purity, ESI/MALDI MS, MS/MS confirmation for long chains
- Shipping
- Ambient with desiccant; blue ice for modified or sensitive peptides
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.